Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m holding. I believe merger worth closer to 26 than current level.
I’m hoping to see VTRS head closer to 19.50 within next two weeks
Same here. Thought I made a drunk buy last night I didn’t remember. What’s up with that? Do we own something that took over this company and we were allotted shares?
I have a feeling there is more to come and hopefully the generic side of the business is profitable
These shares just appeared in my account somehow. Didn't read up on it yet.
THIS IS NOW THE VIATRIS (VTRS) MESSAGE BOARD
Mylan Pfizer Complete Transaction to form Viatris
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.
https://www.nasdaq.com/press-release/pfizer-completes-transaction-to-combine-its-upjohn-business-with-mylan-2020-11-16
The Viatris merger has closed—shares of VTRS begin trading tomorrow:
https://www.businesswire.com/news/home/20201116005378/en
VTRSV (Viatris when issued) shares are now trading on Nasdaq; the VTRSV share price is mirroring MYL, as one would expect since the exchange ratio is 1:1.
3 Reasons Pfizer's Imminent Upjohn-Mylan Merger Is Great News for Investors
Key Points
Pfizer's revenue growth will improve once the Upjohn-Mylan merger wraps up.
The big drugmaker will receive a nice $12 billion cash windfall from the deal.
Pfizer shareholders will still receive a combined dividend (including a dividend from the new entity formed by the merger) that's close to what they receive now.
https://www.nasdaq.com/articles/3-reasons-pfizers-imminent-upjohn-mylan-merger-is-great-news-for-investors-2020-11-06
Mylan Inc. (MYL)
MYL shares will begin trading as VTRS on 11/17/20.
MYL 3Q20 financials—no CC due to pending Viatris merger:
https://www.prnewswire.com/news-releases/mylan-announces-third-quarter-2020-financial-results-and-looks-ahead-to-the-launch-of-viatris-inc-301167725.html
Procedural details on the Viatris closing:
https://www.businesswire.com/news/home/20201105005309/en
Reminder: This message board will become the Viatris board on 11/16/20.
When the Viatris merger closes, this message board will become the Viatris board.
Viatris merger will close on 11/16/20, now that all regulatory clearances have been obtained:
https://finance.yahoo.com/news/mylan-pfizer-receive-clearance-u-173900232.html
Merger recap:
• Viatris will consist of PFE’s Upjohn (branded-generics) division plus all of MYL. The new company will be domiciled in the US and will have senior management and BoD members from both PFE and MYL.
• The “new” PFE following the merger will be a “pure play” branded-biopharmaceutical company.
• Existing PFE shareholders will receive a tax-free distribution of 1 share of Viatris for each 12 shares of PFE; they will retain their existing PFE shares with a slight reduction in the cost basis for tax purposes. Via the spin-off described above, existing PFE shareholders will own a 57% equity stake in Viatris.
• MYL shares will be converted into Viatris shares on a 1:1 basis, and the transaction will be treated as a fully-taxable sale for US MYL shareholders. (Different tax treatment may apply to MYL shareholders in other countries.) MYL shareholders will own a 43% equity stake in Viatris.
• Viatris will pay “new” PFE a lump-sum $12B in cash.
The merger will most definitely prove profitable and we’ll see a share price north of 35.00. The 1/1 stock is a steal. Buying in this range , great idea. Long myl pfe
The likes of smurf5150, shartd748, and Qeerisgood think we're drinking CBD kool aid believing in the promising future, LOL. Platinum and Rainbows
Be interesting to see what the catalyst (or is it catalent, lol) will be. Thank you for reminding me of this board. For some reason I'm limited elsewhere ;))
Going by the historical performance, we believe that the stock price of Mylan (NYSE: MYL), a pharmaceutical company best known for its generic drugs, could offer an upside of over 45% from the current levels. MYL stock trades at $15 currently and it is down 35% from the pre-Covid high of $23 seen in February. Also, MYL stock has declined 2% from the low of $16 seen in March 2020, significantly underperforming the broader markets, with the S&P500 seeing a 53% rise over the same period, as the Fed stimulus largely put investor concerns about the near-term survival of companies to rest.
Mylan Stock Has Over 45% Upside
For Mylan, the sales have trended better than many of the other pharmaceutical companies in this pandemic, as we discuss in the sections below. Mylan’s integration with Pfizer’s Upjohn division will help the company expand geographically, as Upjohn has a strong leadership position in China and emerging markets while Mylan has a significant presence in the U.S. and Europe. In view of the economic growth and with a vaccine in sight for the coronavirus, we believe that MYL stock has more than 45% upside in the near future. Our conclusion is based on our detailed analysis of Mylan stock performance during the current crisis with that during the 2008 recession in an interactive dashboard analysis.
2020 Coronavirus Crisis
Timeline of 2020 Crisis So Far:
12/12/2019: Coronavirus cases first reported in China
1/31/2020: WHO declares a global health emergency.
2/19/2020: Signs of effective containment in China and hopes of monetary easing by major central banks helps S&P 500 reach a record high
3/23/2020: S&P 500 drops 34% from the peak level seen on Feb 19, as Covid-19 cases accelerate outside China. Doesn’t help that oil prices crash in mid-March amid a Saudi-led price war
From 3/24/2020: S&P 500 recovers 56% from the lows seen on Mar 23, as the Fed’s multi-billion dollar stimulus package suppresses near-term survival anxiety and infuses liquidity into the system.
Mylan Inc. (MYL)
https://www.forbes.com/sites/greatspeculations/2020/10/21/mylan-stock-has-over-45-upside/#379d5c2b1464
Fmr LLC Has $5.38 Million Holdings in Mylan (NASDAQ:MYL)
https://www.modernreaders.com/news/2020/10/13/fmr-llc-has-5-38-million-holdings-in-mylan-nasdaqmyl.html
All over the news Mylan Inc. (MYL)
Biocon Biologics and Mylan Announce Launch of Semglee™ in the U.S.
https://www.equitybulls.com/admin/news2006/news_det.asp?id=273228
MYL/Biocon launch Lantus biosimilar for US market:
https://finance.yahoo.com/news/mylan-biocon-biologics-announce-launch-100000761.html
Mylan Launching in USA
Mylan Launching Tecfidera Generic in US
Mylan Inc. (MYL)
https://multiplesclerosisnewstoday.com/news-posts/2020/08/19/mylan-brings-critical-access-to-the-multiple-sclerosis-community-by-launching-a-more-affordable-treatment-option-through-a-first-generic-to-tecfidera/
MYL launches first generic-Tecfidera in US market—pursuant to recent patent win (#msg-156376316):
https://www.prnewswire.com/news-releases/mylan-brings-critical-access-to-the-multiple-sclerosis-community-by-launching-a-more-affordable-treatment-option-through-a-first-generic-to-tecfidera-301114591.html
As a branded drug for BIIB, Tecfidera has had annualized US sales of about $3.8B.
p.s. MYL’s merger with PFE’s Upjohn segment is still on track for closing in 2020.
Mylan Announces Q2 2020 profits
Mylan Inc. (MYL)
https://markets.businessinsider.com/news/stocks/mylan-turns-to-profit-in-q2-updates-2020-outlook-1029477280
Mylan N.V. MYL is expected to beat on earnings when it reports second-quarter 2020 results on Aug 6.
The company’s performance has been excellent, beating earnings estimates in the trailing four quarters by 5.46%, on average. In the last reported quarter, the company’s earnings beat estimates by 2.27%.
https://finance.yahoo.com/news/mylan-myl-report-q2-earnings-150003233.html
Mylan Inc. (MYL)
Hydroxychloroquine Global Market Report 2020-30: Covid 19 Implications and Growth Mylan Inc.
Major players in the hydroxychloroquine market are Bayer AG, Dr. Reddy’s Laboratories, Zydus Cadila, Ipca Laboratories Ltd. , Wallace Pharma, Teva, Mylan, Novartis, and Intas Pharmaceuticals.
https://uk.finance.yahoo.com/news/hydroxychloroquine-global-market-report-2020-165600159.html
(MYL)
MYL shareholders overwhelmingly approve Viatris merger:
https://www.prnewswire.com/news-releases/mylan-shareholders-overwhelmingly-approve-proposed-combination-with-upjohn-301086051.html
The merger is expected to close in 4Q20.
There is no shareholder vote on the Viatris deal by PFE shareholders.
I’m upset because when Mylan switched it’s name to Mylan NV. It passed the taxes to share holders
Mylan Is Eager to Launch Rival Version of Biogen’s Biggest-Selling Drug After Court Win
That sounds big.
https://www.barrons.com/articles/mylan-is-eager-to-launch-rival-version-of-biogens-biggest-selling-drug-51592578852
MYL PR on Tecfidera patent win:
https://www.prnewswire.com/news-releases/mylan-wins-district-court-decision-against-biogens-tecfidera-patent-301079843.html
FDA approves Semglee—MYL’s Lantus biosimilar:
https://www.prnewswire.com/news-releases/mylan-and-biocon-announce-us-fda-approval-of-semglee-insulin-glargine-injection-301074847.html
Mylan Gets OK To Sell Generic Insomnia Drug
https://www.law360.com/articles/1279600/mylan-gets-ok-to-sell-generic-insomnia-drug-during-ip-fight
Viatris deal now expected to close in 4Q20 (rather than 2H20):
https://www.sec.gov/Archives/edgar/data/78003/000119312520157443/d904465d425.htm
Keep watching for the latest covid-19 news here:
https://www.mylan.com/en/news/covid-19-news
It's coming.
(MYL)
Yes yes very nice.
I read the news.
Have a nice day.
(MYL)
That PR was issued on May 12 (#msg-155589466).
Mylan news. Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
Mylan and Gilead Sciences sign global collaboration agreement for the commercialization of remdesivir in 127 low- and middle-income countries
https://finance.yahoo.com/news/mylan-supply-investigational-antiviral-remdesivir-201600559.html
Thanks for the financial advice. MYL
re:
Buy at $1
$MYL back to $1.00
MYL’s—(non-exclusive)—Remdesivir-distribution deal for “less-affluent” countries is squarely in its corporate playbook:
https://www.prnewswire.com/news-releases/mylan-to-supply-investigational-antiviral-remdesivir-for-the-potential-treatment-of-covid-19-301058044.html
MYL 1Q20 items—2020 guidance unchanged...
PR:
https://www.prnewswire.com/news-releases/mylan-reports-first-quarter-2020-results-and-reaffirms-2020-guidance-301056395.html
CC slides:
https://investor.mylan.com/static-files/3c2b08fb-56e2-4852-be34-0f6aa8e47116
MYL’s opt-in decision for RVCNC’s Botox-biosimilar program expected by end of May (#msg-155499241, bottom).
Followers
|
30
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
294
|
Created
|
02/21/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |